CN1901901B - 紫杉醇-脂肪酸结合物及其药物组合物 - Google Patents

紫杉醇-脂肪酸结合物及其药物组合物 Download PDF

Info

Publication number
CN1901901B
CN1901901B CN2004800393077A CN200480039307A CN1901901B CN 1901901 B CN1901901 B CN 1901901B CN 2004800393077 A CN2004800393077 A CN 2004800393077A CN 200480039307 A CN200480039307 A CN 200480039307A CN 1901901 B CN1901901 B CN 1901901B
Authority
CN
China
Prior art keywords
cancer
paclitaxel
omega
use according
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2004800393077A
Other languages
English (en)
Chinese (zh)
Other versions
CN1901901A (zh
Inventor
伊瓦奥·奥吉马
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Publication of CN1901901A publication Critical patent/CN1901901A/zh
Application granted granted Critical
Publication of CN1901901B publication Critical patent/CN1901901B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2004800393077A 2003-10-30 2004-10-28 紫杉醇-脂肪酸结合物及其药物组合物 Expired - Lifetime CN1901901B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51578303P 2003-10-30 2003-10-30
US60/515,783 2003-10-30
PCT/US2004/036027 WO2005041881A2 (en) 2003-10-30 2004-10-28 Taxoid-fatty acid conjugates and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
CN1901901A CN1901901A (zh) 2007-01-24
CN1901901B true CN1901901B (zh) 2012-07-04

Family

ID=34549443

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2004800393077A Expired - Lifetime CN1901901B (zh) 2003-10-30 2004-10-28 紫杉醇-脂肪酸结合物及其药物组合物

Country Status (7)

Country Link
US (1) US7820839B2 (enExample)
EP (1) EP1703904B1 (enExample)
JP (1) JP4884228B2 (enExample)
CN (1) CN1901901B (enExample)
AU (1) AU2004285529A1 (enExample)
CA (1) CA2544128A1 (enExample)
WO (1) WO2005041881A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2544128A1 (en) 2003-10-30 2005-05-12 The Research Foundation Of State University Of New York Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
WO2007021957A2 (en) 2005-08-12 2007-02-22 Research Foundation Of State University Of New York Fluorotaxoids
WO2008021242A2 (en) * 2006-08-10 2008-02-21 The Research Foundation Of State University Of New York Fluorotaxoid-fatty acid conjugates and pharmaceutical compositions thereof
CN101225094A (zh) * 2007-01-18 2008-07-23 天津和美生物技术有限公司 具有抗癌活性的蒽醌四环类化合物
US20090022727A1 (en) 2007-01-26 2009-01-22 Alza Corp. Injectable, nonaqueous suspension with high concentration of therapeutic agent
WO2014145817A2 (en) * 2013-03-15 2014-09-18 Children's Medical Center Corporation Novel therapeutic target for the treatment of cancers and related therapies and methods
CN106390122A (zh) * 2015-07-31 2017-02-15 舟山三合生物科技有限公司 化疗类抗癌药口服制剂组合物
CN105343004A (zh) * 2015-09-14 2016-02-24 东北林业大学 一种二十二碳六烯酸靶向多西紫杉醇纳米药物的制备方法
JP7518604B2 (ja) * 2016-06-07 2024-07-18 タルガジェニックス，インコーポレイテッド タキソイド薬物のナノエマルション組成物、並びに標的癌細胞及び癌幹細胞に対するその使用方法
CA3121615A1 (en) * 2017-12-20 2019-06-27 Targagenix, Inc. Combination taxoid nanoemulsion with immunotherapy in cancer
CN110201182B (zh) * 2019-06-21 2022-09-27 山东大学 一种紫杉醇-dha-右旋糖酐偶联聚合物及其合成方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6458976B1 (en) * 1994-10-28 2002-10-01 The Research Foundation Of State University Of New York Taxoid anti-tumor agents, pharmaceutical compositions, and treatment methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100411A (en) * 1994-10-28 2000-08-08 The Research Foundation Of State University Of New York Taxoid anti-tumor agents and pharmaceutical compositions thereof
US6500858B2 (en) * 1994-10-28 2002-12-31 The Research Foundation Of The State University Of New York Taxoid anti-tumor agents and pharmaceutical compositions thereof
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
ATE196844T1 (de) * 1996-05-22 2000-10-15 Protarga Inc Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
KR20020000147A (ko) * 1999-03-09 2002-01-04 니겔 엘. 웹 지방산-항암제 결합체 및 그의 용도
CA2544128A1 (en) 2003-10-30 2005-05-12 The Research Foundation Of State University Of New York Taxoid-fatty acid conjugates and pharmaceutical compositions thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458976B1 (en) * 1994-10-28 2002-10-01 The Research Foundation Of State University Of New York Taxoid anti-tumor agents, pharmaceutical compositions, and treatment methods
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes

Also Published As

Publication number Publication date
WO2005041881A3 (en) 2005-12-08
WO2005041881A2 (en) 2005-05-12
WO2005041881A8 (en) 2006-06-29
CA2544128A1 (en) 2005-05-12
US7820839B2 (en) 2010-10-26
US20070088076A1 (en) 2007-04-19
EP1703904B1 (en) 2013-02-13
AU2004285529A1 (en) 2005-05-12
EP1703904A4 (en) 2011-01-19
CN1901901A (zh) 2007-01-24
JP4884228B2 (ja) 2012-02-29
JP2007510648A (ja) 2007-04-26
EP1703904A2 (en) 2006-09-27

Similar Documents

Publication Publication Date Title
Sati et al. Paclitaxel and its semi-synthetic derivatives: comprehensive insights into chemical structure, mechanisms of action, and anticancer properties
CN108478794B (zh) 光敏剂-化疗药“光化一体”小分子前药及其自组装纳米粒的构建
TWI316942B (en) Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US11066433B2 (en) Pentaaza macrocyclic ring complexes possessing oral bioavailability
KR20020082458A (ko) 탁산 프로드럭
CN1901901B (zh) 紫杉醇-脂肪酸结合物及其药物组合物
JP2013516486A (ja) 脂肪酸フマル酸塩誘導体およびそれらの使用
CN101300009B (zh) 作为化学辐射敏化剂的喜树碱衍生物
Li et al. Synthesis and biological activity of salinomycin-hydroxamic acid conjugates
Wang et al. Design and synthesis of novel artemisinin derivatives with potent activities against colorectal cancer in vitro and in vivo
AU2012275953B2 (en) Acid-labile lipophilic prodrugs of cancer chemotherapeutic agents
Lin et al. Recent strategies in the development of taxane anticancer drugs
CN101328159B (zh) 紫杉烷前体抗癌药及其药物组合物和用途
JP2003055360A (ja) Ｃ１０エステル置換タキサン
WO2012036180A1 (ja) キサントン誘導体およびその用途
CN105777769B (zh) 一种7-乙基-10-羟基喜树碱的衍生物及其制备方法与应用
CN108699060A (zh) 结合有脂肪酸的恩替卡韦衍生化合物及其药学用途
US20040122081A1 (en) Pharmaceutical compositions and methods of using taxane derivatives
US7615653B2 (en) Anti-tuberculosis taxane compounds
CN101830819A (zh) 苯丁酰基姜黄素衍生物及其在制备抗肿瘤药物中的应用
EP2213667A1 (en) Cephalomannine derivatives and their preparation, medicinal composition and use
US20050054716A1 (en) Pharmaceutical compositions and methods of using taxane derivatives
TWI286552B (en) C10 carbonate substituted taxanes
JP2003055361A (ja) Ｃ１０カーボネート置換タキサン
CN119097621A (zh) 一种药物组合物及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20120704